Changchun BCHT Biotechnology Co.
Headquarters country
China
Registry sponsor category
Industry
- Other names
- Changchun BCHT Biotechnology Co.
- Company name
- Changchun BCHT Biotechnology Co.
- Organisation type
- Industry
- Registered legal name
- 长春百克生物科技股份公司
- Registry sponsor category
- Industry
- Legal Entity Identifier (LEI)
- 8368000E14LIZR0C4328
Related records
Trials (21)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
- A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)
- A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)
- A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
- A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)
- A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)
- A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine
- A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine
- A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)
- Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
- Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
- Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
- Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
- Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
- Study on Efficacy of Attenuated Zoster Vaccine, Live
- The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
- The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
- To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants